Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

Table 3 Number of patients in subgroup analysis, adherence to therapy, and hazard ratios for stopping treatment

	Patients included February through December 1999	Patients included February 2000 through June 2001	Adherence to therapy after 1 year (2 years)	Hazard ratio (95% CI)	Hazard ratio (95% CI), time-dependent Cox regression analysis
Etanercept and MTX	58	5^a	90% (87%)	3.27 (1.76; 6.08)	3.15 (1.84; 5.39)
Infliximab and MTX	12^a	206	68% (60%)
Etanercept as monotherapy	100	13^a	77% (69%)	4.26 (2.60; 7.00)	2.75 (1.70; 4.46)
Infliximab as monotherapy	0^a	56	45% (27%)

^aPatients not included in analysis. The hazard ratios were adjusted for differences in age, gender, 28-joint disease activity score (DAS28), health assessment questionnaire (HAQ) score, disease duration, previous disease-modifying antirheumatic drugs, and C-reactive protein (CRP) level. Data presented in the last column use HAQ score, DAS28, and CRP level as time-dependent covariates. For details, see Results. CI, confidence interval; MTX, methotrexate.

ISSN: 1478-6362